跳至主要内容
临床试验/NCT03246542
NCT03246542已完成不适用

Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome.

AYMAN ABDELKADER MOHAMED ABDELKADER0 个研究点目标入组 100 人开始时间: 2015年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
主要终点
laboratory changes after 48 hours of delivery

研究概览

简要总结

HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia. And may occasionally be confused with other diseases complicating pregnancy such as acute fatty liver of pregnancy, gastroenteritis, hepatitis, appendicitis, gallbladder disease, immune thrombocytopenia, lupus flare, antiphospholipid syndrome, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and nonalcoholic fatty liver disease. The distinction between thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and severe preeclampsia is important for therapeutic and prognostic reasons. However, the clinical and histological features are so similar that establishing the correct diagnosis is often difficult; furthermore, these disorders may occur concurrently.

详细描述

When TTP/HUS does occur during pregnancy, they often are confused initially with obstetric diagnoses such as severe preeclampsia; hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; acute fatty liver of pregnancy; eclampsia, and antiphospholipid antibody syndrome. This might be related to the fact that the disease entity is rare and often is unexpected. Nevertheless, a delay in diagnosis of TTP/HUS may result in life-threatening maternal and fetal consequences. Aim of the current study was to compare the quantitative assessment of schistocytes in peripheral blood smear between women initially diagnosed as HELLP syndrome who showed no spontaneous resolution within 48 hrs after delivery and those who showed spontaneous resolution within 48 hrs after delivery which may help in decreasing the maternal mortality rate .

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Gestational age more than 20 weeks.
  • Age from18 to 40 years old.
  • Fulfilled criteria for the diagnosis of severe preeclampsia.
  • Fulfilled criteria for the diagnosis of HELLP syndrome.
  • Diagnostic criteria for severe preeclampsia(one of the following):
  • Blood pressure of 160 mm Hg systolic or higher or 110 mm Hg diastolic or higher on two occasions at least 6 hours apart while the patient is on bed rest (unless antihypertensive therapy is intiated befor this time).
  • New onest Cerebral or visual disturbances.
  • Pulmonary edema or cyanosis.
  • Sever persistant epigastric or right upper-quadrant pain unresponsive to medication and not accounted for by alternative diagnosis, or both.
  • Impaired liver function as indicated by abnormally elevated blood concentration of liver enzymes (to twic normal concentration).
  • Thrombocytopenia (platlet count less than 100, 000 per microliter.
  • Diagnostic criteria for HELLP syndrome:
  • Hemolysis documented by an increased LDH level and progressive anemia .
  • Hepatic dysfunction documented by an LDH level >600 IU/L, elevated liver enzymes documented by AST >40 IU/L, ALT>40 IU/L, or both .
  • Thrombocytopenia documented by a platelet nadir less than 150, 000 cells/mm³. Thrombocytopenia is subclassified as class one HELLP syndrome: platelet nadir ≤50, 000 cells/mm³, class two HELLP syndrome: platelet nadir ≤100, 000 cells/mm³, or class three HELLP syndrome: platelet nadir ≤150, 000 cells/mm³..
  • Anticepation of Microangiopathic Hemolytic Anemia:
  • Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome should be considered in all pregnant women with severe thrombocytopenia, severe anemia, and elevated lactate dehydrogenase enzyme.

排除标准

  • any non included criteria

结局指标

主要结局

laboratory changes after 48 hours of delivery

时间窗: 48 hours

full blood count, liver function tests( AST, ALT, Bilirubin), kidney function (serum creatinine level), coagulation profile (INR, PTT, PT)

次要结局

未报告次要终点

研究者

发起方
AYMAN ABDELKADER MOHAMED ABDELKADER
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

AYMAN ABDELKADER MOHAMED ABDELKADER

doctor

Ain Shams Maternity Hospital

相似试验